These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 7969204)

  • 1. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment.
    Goetz CG; Stebbins GT; Shale HM; Lang AE; Chernik DA; Chmura TA; Ahlskog JE; Dorflinger EE
    Mov Disord; 1994 Jul; 9(4):390-4. PubMed ID: 7969204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial.
    Siderowf A; McDermott M; Kieburtz K; Blindauer K; Plumb S; Shoulson I;
    Mov Disord; 2002 Jul; 17(4):758-63. PubMed ID: 12210871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rating impairment and disability in Parkinson's disease: evaluation of the Unified Parkinson's Disease Rating Scale.
    van Hilten JJ; van der Zwan AD; Zwinderman AH; Roos RA
    Mov Disord; 1994 Jan; 9(1):84-8. PubMed ID: 8139609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teaching program for the Unified Dyskinesia Rating Scale.
    Goetz CG; Nutt JG; Stebbins GT; Chmura TA
    Mov Disord; 2009 Jul; 24(9):1296-8. PubMed ID: 19425060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interrater reliability of the Unified Parkinson's Disease Rating Scale motor examination.
    Richards M; Marder K; Cote L; Mayeux R
    Mov Disord; 1994 Jan; 9(1):89-91. PubMed ID: 8139610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Unified Dyskinesia Rating Scale: presentation and clinimetric profile.
    Goetz CG; Nutt JG; Stebbins GT
    Mov Disord; 2008 Dec; 23(16):2398-403. PubMed ID: 19025759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reliability of patient completion of the historical section of the Unified Parkinson's Disease Rating Scale.
    Louis ED; Lynch T; Marder K; Fahn S
    Mov Disord; 1996 Mar; 11(2):185-92. PubMed ID: 8684390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Automatic assessment of levodopa-induced dyskinesias in daily life by neural networks.
    Keijsers NL; Horstink MW; Gielen SC
    Mov Disord; 2003 Jan; 18(1):70-80. PubMed ID: 12518302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic evaluation of rating scales for impairment and disability in Parkinson's disease.
    Ramaker C; Marinus J; Stiggelbout AM; Van Hilten BJ
    Mov Disord; 2002 Sep; 17(5):867-76. PubMed ID: 12360535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease.
    Tison F; Yekhlef F; Chrysostome V; Balestre E; Quinn NP; Poewe W; Wenning GK
    Mov Disord; 2002 Jul; 17(4):701-9. PubMed ID: 12210859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantifying drug-induced dyskinesias in the arms using digitised spiral-drawing tasks.
    Liu X; Carroll CB; Wang SY; Zajicek J; Bain PG
    J Neurosci Methods; 2005 May; 144(1):47-52. PubMed ID: 15848238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor structure of the Unified Parkinson's Disease Rating Scale: Motor Examination section.
    Stebbins GT; Goetz CG
    Mov Disord; 1998 Jul; 13(4):633-6. PubMed ID: 9686766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reliability of the Columbia scale for assessing signs of Parkinson's disease.
    Hely MA; Chey T; Wilson A; Williamson PM; O'Sullivan DJ; Rail D; Morris JG
    Mov Disord; 1993 Oct; 8(4):466-72. PubMed ID: 8232356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
    Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H
    Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ambulatory motor assessment in Parkinson's disease.
    Keijsers NL; Horstink MW; Gielen SC
    Mov Disord; 2006 Jan; 21(1):34-44. PubMed ID: 16127718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials.
    Rabey JM; Bass H; Bonuccelli U; Brooks D; Klotz P; Korczyn AD; Kraus P; Martinez-Martin P; Morrish P; Van Sauten W; Van Hilten B
    Clin Neuropharmacol; 1997 Aug; 20(4):322-37. PubMed ID: 9260730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global versus factor-related impression of severity in Parkinson's disease: a new clinimetric index (CISI-PD).
    Martínez-Martín P; Forjaz MJ; Cubo E; Frades B; de Pedro Cuesta J;
    Mov Disord; 2006 Feb; 21(2):208-14. PubMed ID: 16161158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group.
    Martínez-Martín P; Gil-Nagel A; Gracia LM; Gómez JB; Martínez-Sarriés J; Bermejo F
    Mov Disord; 1994 Jan; 9(1):76-83. PubMed ID: 8139608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.